Applied Therapeutics (APLT) Competitors $1.10 -0.05 (-4.35%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends APLT vs. CRMD, MREO, XERS, ABVX, MGTX, RNAC, GLUE, TKNO, ORGO, and CDXCShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include CorMedix (CRMD), Mereo BioPharma Group (MREO), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Cartesian Therapeutics (RNAC), Monte Rosa Therapeutics (GLUE), Alpha Teknova (TKNO), Organogenesis (ORGO), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. CorMedix Mereo BioPharma Group Xeris Biopharma ABIVAX Société Anonyme MeiraGTx Cartesian Therapeutics Monte Rosa Therapeutics Alpha Teknova Organogenesis ChromaDex Applied Therapeutics (NASDAQ:APLT) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability. Is APLT or CRMD more profitable? CorMedix's return on equity of -79.21% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -260.75% -76.04% CorMedix N/A -79.21%-64.68% Do institutionals and insiders hold more shares of APLT or CRMD? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 8.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 5.2% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to APLT or CRMD? In the previous week, Applied Therapeutics had 4 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Applied Therapeutics and 3 mentions for CorMedix. CorMedix's average media sentiment score of 1.66 beat Applied Therapeutics' score of 0.07 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in APLT or CRMD? Applied Therapeutics received 58 more outperform votes than CorMedix when rated by MarketBeat users. However, 73.33% of users gave CorMedix an outperform vote while only 58.39% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformApplied TherapeuticsOutperform Votes8058.39% Underperform Votes5741.61% CorMedixOutperform Votes2273.33% Underperform Votes826.67% Do analysts rate APLT or CRMD? Applied Therapeutics currently has a consensus target price of $6.60, suggesting a potential upside of 500.00%. CorMedix has a consensus target price of $15.20, suggesting a potential upside of 77.99%. Given Applied Therapeutics' higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86CorMedix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, APLT or CRMD? CorMedix has higher revenue and earnings than Applied Therapeutics. CorMedix is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics-$212K-603.73-$119.76M-$1.61-0.68CorMedix$12.26M42.26-$46.34M-$0.81-10.54 Which has more volatility and risk, APLT or CRMD? Applied Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. SummaryCorMedix beats Applied Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.99M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-0.6810.80135.3117.54Price / Sales-603.73287.861,260.42139.42Price / CashN/A56.6540.5837.95Price / Book-5.505.394.884.92Net Income-$119.76M$152.04M$118.89M$225.78M7 Day Performance-11.29%-4.32%15.96%-1.56%1 Month Performance-87.28%2.80%15.87%6.68%1 Year Performance-62.84%17.30%34.78%22.48% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.517 of 5 stars$1.10-4.3%$6.60+500.0%-62.8%$127.99M$-212,000.00-0.6830Gap DownCRMDCorMedix2.3198 of 5 stars$8.39+0.1%$15.20+81.2%+158.0%$509.08M$12.26M-10.3530Positive NewsMREOMereo BioPharma Group2.1906 of 5 stars$3.27-12.6%$7.40+126.3%+65.9%$507.33M$1M0.0040Positive NewsGap DownHigh Trading VolumeXERSXeris Biopharma3.907 of 5 stars$3.40+3.7%$4.87+43.1%+68.8%$506.87M$163.91M-7.29290Positive NewsABVXABIVAX Société Anonyme2.2762 of 5 stars$7.98+12.2%$38.67+384.5%-24.4%$505.52MN/A0.0061Positive NewsGap DownMGTXMeiraGTx4.2578 of 5 stars$6.42+4.9%$23.50+266.0%+42.2%$501.74M$13.93M-5.06300RNACCartesian Therapeutics2.644 of 5 stars$19.00+1.7%$43.00+126.3%-18.4%$482.98M$26M-0.3537Positive NewsGap DownGLUEMonte Rosa Therapeutics2.4567 of 5 stars$7.78+2.9%$16.00+105.7%+53.4%$477.98M$14.98M-4.1390TKNOAlpha Teknova0.8898 of 5 stars$8.81+9.7%$5.00-43.2%+131.5%$469.66M$36.68M-11.73240Gap UpORGOOrganogenesis4.2704 of 5 stars$3.52+3.5%$5.33+51.5%-4.8%$466.68M$433.14M-56.67950Insider TradeCDXCChromaDex4.6785 of 5 stars$6.10-0.3%$8.00+31.1%+334.8%$465.94M$91.67M620.00106Analyst Downgrade Related Companies and Tools Related Companies CorMedix Alternatives Mereo BioPharma Group Alternatives Xeris Biopharma Alternatives ABIVAX Société Anonyme Alternatives MeiraGTx Alternatives Cartesian Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Alpha Teknova Alternatives Organogenesis Alternatives ChromaDex Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
